# A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia

> **NCT04117880** · PHASE2 · WITHDRAWN · sponsor: **PTC Therapeutics**

## Conditions studied

- Aniridia

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT04117880
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-31
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study cancelled before protocol was implemented.
- **Last updated:** 2019-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04117880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04117880, "A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04117880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*